Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DCC-2618 (Ripretinib) in Advanced GIST (China)
NCT04282980Phase 2Completed
- Sponsor
- Zai Lab
- Start
- Apr 2020
- Primary completion
- Feb 2021
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of ripretinib in gastrointestinal stromal tumor (GIST), sponsored by Zai Lab. Started Apr 2020; status: completed.
02
Drugs
ripretinib
03
Conditions
gastrointestinal stromal tumor (GIST)
Beyond the preview
Go deeper on NCT04282980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04282980.